NUAK1 Promotes Diabetic Kidney Disease by Accelerating Renal Tubular Senescence via the ROS/P53 Axis.
Summary
Across multiple DKD models, NUAK1 was upregulated and mechanistically drove ROS/p53–mediated tubular senescence, inflammation, and fibrosis. Genetic and pharmacologic inhibition—including Asiatic acid as a binding inhibitor—attenuated renal injury, identifying NUAK1 as a tractable therapeutic target.
Key Findings
- NUAK1 expression is increased in DKD across human cells, multiple mouse models, and human PBMCs.
- Inhibition of NUAK1 (siRNA, pharmacological inhibitors, or tubule-targeted AAV-shRNA) reduced ROS/p53-dependent tubular senescence, oxidative stress, inflammation, and fibrosis in vitro and in vivo.
- ETS1 binds the NUAK1 promoter and drives transcriptional activation in DKD.
- Asiatic acid directly binds NUAK1, suppresses NUAK1 signaling and downstream pathology, and ameliorates renal injury in DKD models.
Clinical Implications
NUAK1 may serve as a biomarker and drug target in DKD; optimizable NUAK1 inhibitors (derivatives of Asiatic acid) warrant preclinical pharmacology and eventual clinical trials to slow renal decline.
Why It Matters
This study links a defined kinase (NUAK1) to tubular senescence and DKD progression and proposes a readily available natural compound scaffold for inhibition, bridging mechanism to therapeutic development.
Limitations
- Translational gap: no human kidney tissue intervention data or clinical endpoints
- Specificity and off-target profiles of Asiatic acid and NUAK1 inhibitors remain to be fully characterized
Future Directions
Develop and optimize selective NUAK1 inhibitors; validate NUAK1 as a biomarker in human DKD cohorts; test efficacy and safety in preclinical pharmacology and early-phase clinical trials.
Study Information
- Study Type
- Basic/Mechanistic Research
- Research Domain
- Pathophysiology/Treatment
- Evidence Level
- IV - Preclinical mechanistic evidence using in vitro and in vivo models with human supporting data
- Study Design
- OTHER